guest ::
| Home > Publications database > Immunohistochemistry-based hypoxia-immune prognostic classifier for head-and-neck cancer patients undergoing chemoradiation - Post-hoc analysis from a prospective imaging trial. |
| Home > Publications database > Immunohistochemistry-based hypoxia-immune prognostic classifier for head-and-neck cancer patients undergoing chemoradiation - Post-hoc analysis from a prospective imaging trial. |
| Journal Article | DKFZ-2021-00704 |
; ; ; ; ; ; ; ; ;
2021
Elsevier Science
Amsterdam [u.a.]
This record in other databases: 
Please use a persistent id in citations: doi:10.1016/j.radonc.2021.03.014
Abstract: As both tumor hypoxia and an immunosuppressing tumor microenvironment hamper the anti-tumor activity of radiotherapy in head-and-neck squamous cell carcinoma (HNSCC), we aimed to develop an immunohistochemistry-based hypoxia-immune classifier.39 patients receiving definitive chemoradiation for HNSCC within a prospective trial were included in this analysis. Baseline tumor samples were analyzed for the hypoxia marker carbonic anhydrase IX (CAIX) and tumor-infiltrating lymphocytes (TILs) and were correlated with [18F]-misonidazole ([18F]FMISO) PET measurements. The impact of the biomarkers on the locoregional control (LRC) was examined using Cox analyses and concordance index statistics.Low CAIX (HR=0.352, 95%CI 0.124-1.001, p=0.050) and high TIL levels (HR=0.308, 95%CI 0.114-0.828, p=0.020) were independent parameters for improved LRC and did not correlate with each other (Spearman's ρ=0.034, p=0.846). Harrell's C was 0.66 for CAIX and TIL levels alone and 0.71 for the combination. 2-year LRC was 73%, 62% and 11% for the prognostically good (CAIXlow/TILhigh), intermediate (CAIXlow/TILlow or CAIXhigh/TILhigh) and poor groups (CAIXhigh/TILlow), respectively (p=0.001). Focusing on T lymphocytes, the hypoxia-immune classifier could still stratify between favorable (CAIXlow/CD3+ TILhigh), intermediate (CAIXlow/CD3+ TILlow or CAIXhigh/CD3+ TILhigh) and poor subgroups (CAIXhigh/CD3+ TILlow) with a 2-year LRC of 80%, 59% and 14%, respectively (p=0.001). There was a positive correlation between baseline CAIX levels and [18F]FMISO SUV in week 2 of chemoradiation (ρ=0.324, p=0.050), indicating an association between higher baseline CAIX expression and tumor hypoxia persistence.We developed a clinically feasible hypoxia-immune prognostic classifier for HNSCC patients based on pre-treatment immunohistochemistry. However, external validation is required to determine the prognostic value and the potential usage for personalized radiation oncology.
Keyword(s): Carbonic anhydrase IX ; FMISO PET ; Head-and-neck squamous cell carcinoma ; Hypoxia ; Radiotherapy biomarker ; Tumor-infiltrating lymphocytes
; BIOSIS Previews ; Biological Abstracts ; Clarivate Analytics Master Journal List ; Current Contents - Clinical Medicine ; Ebsco Academic Search ; Essential Science Indicators ; IF < 5 ; JCR ; Nationallizenz
; SCOPUS ; Science Citation Index Expanded ; Web of Science Core Collection
|
The record appears in these collections: |
